COST Action CA17140 Final Conference

Final Program

October 25, 2022

13^{30} – 13^{40} Opening and welcome addresses from the Action Chair
13^{40} – 13^{50} Overview of WG1 activity (Tomas Strasak, CZ, WG1 vice-leader)
13^{50} – 14^{20} *Nanoactuators for therapy and diagnosis*, **Jesus M. de la Fuente** (ES, **KN1**)
14^{20} – 14^{50} *Unlocking the potential of antibody-drug conjugates in oncology: a focus on HER2 signaling pathway*, **Joseph Ciccolini** (FR, **KN2**)
14^{50} – 15^{10} *A phthalocyanine-cored dendrimer for photodynamic therapy*, **Jørn B. Christensen** (DK, **OCP1**)
15^{10} – 15^{30} *Evaluation of carbosilane and bis-MPA based dendrimers as anticancer agents*, **Natalia Sanz del Olmo** (SE, **OCP2**)
15^{30} – 15^{50} *Triggerable nanomedicines for targeted cancer therapy*, **Wafa Al Jamal** (UK, **OCP3**)
15^{50}– 16^{20} *Ruthenium and copper carbosilane metallodendrimers as anticancer agents*, **Francisco Javier de la Mata** (ES, **KN3**)

16^{20}– 16^{30} Coffee break (CB)

16^{30} – 17^{00} *Nanomechanical Phenotype – novel, fast and clinically validated physical biomarker for characterization of cellular and extracellular structures*, **Marko Loparic** (CH, **KN4**)
17^{00} – 17^{20} *Thiolated liposomes as mucoadhesive oral delivery system*, **Ruth Prassl** (AT, **OCP4**)
17^{20} – 17^{40} *Optimization of tyrosine kinase inhibitor-loaded gold nanoparticles for triggered antileukemic drug release and cytotoxic evaluation*, **Sanda Boca-Farcau** (RO, **OCP5**)
17^{40} – 18^{00} *Surface modifying PLGA nanoparticles for GBM specific targeting*, **Jason T. Duskey** (IT, **OCP6**)
18^{00} – 18^{20} *Synthesis and in vitro proof-of-concept studies on nanoparticles (iron oxide/gold) targeting PSMA (Prostate Specific Membrane Antigen) and GRP (Gastrin Releasing Peptide) receptors for PET/MR and SPECT imaging of prostate cancer*, **Christos Liolios** (EL, **OCP7**)
18^{20}– 18^{30} Concluding remarks

Evening: social dinner

Funded by the European Union

October 26, 2022

9^{00} – 9^{10} Overview of WG2 activity (Ivana Vinkovic Vrcek, HR, WG2 leader)
9^{10} – 9^{40} *Iron oxide nanoflowers as excellent heating agents for magnetic hyperthermia cancer therapy*, **Nguyen Thi Kim Thanh** (UK, **KN5**)
9^{40} – 10^{00} *Cancer therapy using porous silicon nanocarriers with stimulus-cleavable linkers*, **Nicolas Voelker** (AUS, **OCR1**)
10^{00} – 10^{20} *Biosensors for cancer diagnostics and targeted drug delivery based on DNA aptamers*, **Tibor Hianik** (SK, **OCR2**)
10^{20} – 10^{40} *Synthetic glycoconjugates - galectin ligands with a therapeutic potential,* **Pavla Bojarova** (CZ, **OCR3**)
10^{40} – 11^{00} *Self-assembling ionizable dendrimers for biomedical applications*, **Dinesh Dhumal** (FR, **OCR4**)

11^{00} – 11^{10} CB

11^{10} – 11^{40} *Beyond nucleic acids as vaccines: curing ocular diseases with nucleic acids?*, **Stefaan C. De Smedt** (BE, **KN6**)
11^{40} – 12^{00} *Design of novel nanoformulation to decrease cardiotoxicity of doxorubicin*, **Krunoslav Ilic** (HR, **OCP8**)
12^{00} – 12^{20} *Carbosilane glycodendrimers for anticancer drug delivery*, **Monika Mullerova** (CZ, **OCP9**)
12^{20} – 12^{50} *Nanoparticles for glioblastoma therapy,* **Valentin Cena** (ES, **KN7**)

12^{50} – 13^{50} Lunch Break

13^{50} – 14^{00} Overview of WG3 activity (Carlo V. Catapano, CH, WG3 leader)
14^{00}– 14^{30} *Multifunctional nanomedicines of chemotherapeutic and antiangiogenic effect to target glioblastoma are validated in 3D tumor microtissue-forming unit and in vivo orthotopic model,* **Bruno Sarmento** (PT, **KN8**)
14^{30} – 14^{50} *Co-clinical organoid platform for individualization of cancer chemotherapy*, **Ulf Kahlert** (DE, **OCP10**)
14^{50} – 15^{10} *NaDeNo – Unleashing the potential of hard-to-deliver drugs*, **Yrr Morch** (NO, **OCP11**)
15^{10} – 15^{30} *ICG-tagged aptamer as drug delivery system for in vitro and in vivo malignant melanoma models*, **Jessica Lopez-Nunez** (PT, **OCR5**)

15^{30} – 15^{40} CB

15^{40} – 15^{50} Overview of WG4 activity (Enrico Catalano, IT, WG4 vice-leader)
15^{50} – 16^{20} *Cryo-EM of drug delivery nano vehicles*, **Dganit Danino** (IL, **KN9**)

Funded by the European Union

16^{20} – 16^{40} *Development of an occupational risk assessment for nanobiomaterials used in advanced therapy medicinal product for cancer treatment*, **Virginia Cazzagon** (IT, **OCP12**)
16^{40} – 17^{00} *Testing extracellular vesicles as cisplatin carriers in lung cancer on a chip platform*, **Arturs Abols** (LV, **OCP13**)
17^{00} – 17^{20} *A new perspective for cancer prevention using magnetic nanoparticles for the therapy of adiposopathy by magneto-mechanical effect*, **Oliviero Gobbo** (IE, **OPC14**)
17^{20} – 17^{40} *Potential antitumor application of polyphenol-conjugated turnip mosaic virus-derived nanoparticles*, **Corina Lorz** (ES, **OCP15**)
17^{40} – 18^{00} *Fucoidan/dendrimer nanoparticles for glioblastoma treatment: anti-angiogenic behavior and siRNA delivery studies,* **Helena Tomas** (PT, **OCP16**)
18^{00} – 18^{30} *Hard road to good manufacturing practices for nanomedicine*, **Nazende Gunday Tureli** (DE, **KN10**)
18^{30} – 18^{40}Closing and farewell

Funded by the European Union